Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Arrowhead Pharmaceuticals clinical trials
The registry lists 51 studies whose lead sponsor is Arrowhead Pharmaceuticals or one of 1 company grouped under it. 10 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 13, 2026.
Keep track of what changes. Save the Arrowhead Pharmaceuticals studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Arrowhead Pharmaceuticals.
- Arrowhead Pharmaceuticals50 studiesSame company
Something wrong?
- Calando Pharmaceuticals1 study →Subsidiary
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 50 of 51. Browse all 51 →
- Study of ARO-DIMERPA in Adult Participants With Mixed HyperlipidemiaRecruitingNCT07223658Phase 1/2
- Study of Zodasiran in Adolescent Participants With Homozygous Familial HypercholesterolemiaRecruitingNCT07473843Phase 3
- A Trial to Evaluate the Efficacy and Safety of ARO-INHBE in Adults With Metabolic Dysfunction-Associated SteatohepatitisNot yet recruitingNCT07859813Phase 2
- Study of Inhaled ARO-RAGE in Allergen-induced Mild AsthmaRecruitingNCT07241546Phase 2
- A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes MellitusRecruitingNCT06700538Phase 1/2
- Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute PancreatitisRecruitingNCT06880770Phase 3
- Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's DiseaseRecruitingNCT07221344Phase 1/2
- A First-In-Human Study of ARO-033 in Adult ParticipantsRecruitingNCT07662096Phase 1
- A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes MellitusRecruitingNCT06937203Phase 1/2
- Treatment Protocol of Plozasiran in Adults With High-Risk Severe Hypertriglyceridemia (SHTG) and in Adults and Adolescents With FCSAvailableNCT06796426
- Study of Plozasiran in Adults With Severe HypertriglyceridemiaCompletedNCT06347016Phase 3
- Study of Plozasiran (ARO-APOC3) in Adults With Severe HypertriglyceridemiaCompletedNCT06347003Phase 3
- Long-Term Safety and Efficacy of Plozasiran in Adults With HypertriglyceridemiaActive, not recruitingNCT06822790Phase 3
- Phase 3 Study of Plozasiran in Adults With HypertriglyceridemiaCompletedNCT06347133Phase 3
- Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung DiseaseTerminatedNCT05292950Phase 1/2
- A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)Active, not recruitingNCT07037771Phase 3
- Study of ARO-MMP7 Inhalation Solution in Healthy Participants and Participants With Idiopathic Pulmonary FibrosisCompletedNCT05537025Phase 1/2
- Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2Active, not recruitingNCT06672445Phase 1
- Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH)TerminatedNCT05217667Phase 2
- Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)CompletedNCT05089084Phase 3
- Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal DiseaseCompletedNCT05083364Phase 1/2
- Study of ARO-CFB in Adult Healthy VolunteersCompletedNCT06209177Phase 1
- Study of ARO-APOC3 in Adults With DyslipidemiaCompletedNCT05413135Phase 2
- Study of Plozasiran (ARO-APOC3) in Adults With Mixed DyslipidemiaCompletedNCT04998201Phase 2
- Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung DiseaseCompletedNCT05276570Phase 1/2
- Study to Evaluate ARO-APOC3 in Adults With Severe HypertriglyceridemiaCompletedNCT04720534Phase 2
- Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)TerminatedNCT02577029Phase 2
- A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus InfectionTerminatedNCT02604212Phase 2
- A Study of ARC-520 at Varying Infusion Rates in Healthy Adult VolunteersCompletedNCT02535416Phase 1
- A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) InfectionTerminatedNCT02065336Phase 2
- Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) InfectionTerminatedNCT02738008Phase 2
- A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) InfectionTerminatedNCT02604199Phase 2
- A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD)TerminatedNCT02363946Phase 1
- A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB)TerminatedNCT02797522Phase 1
- Safety and Tolerability Study of ARC-520 in Healthy VolunteersCompletedNCT01872065Phase 1
- Study of ARC-520 in Patient With Chronic Hepatitis B VirusWithdrawnNCT02349126Phase 2
- Study of ARO-ANG3 in Healthy Volunteers and in Dyslipidemic PatientsCompletedNCT03747224Phase 1
- Study of ARO-AAT in Normal Adult VolunteersCompletedNCT03362242Phase 1
- Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome (FCS)CompletedNCT03783377Phase 1
- Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin LevelsWithdrawnNCT02900183Phase 2
- Study of ARO-ENaC in Healthy Volunteers and in Patients With Cystic FibrosisTerminatedNCT04375514Phase 1/2
- Study of ARO-ANG3 in Adults With Mixed DyslipidemiaCompletedNCT04832971Phase 2
- Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)CompletedNCT03945292Phase 2
- Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B VirusTerminatedNCT02452528Phase 2
- Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV)CompletedNCT03365947Phase 1/2
- Study of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)CompletedNCT03946449Phase 2
- Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell CarcinomaCompletedNCT04169711Phase 1
- Study of ARO-HSD in Healthy Volunteers and Patients With Non-Alcoholic Steatohepatitis (NASH) or Suspected NASHCompletedNCT04202354Phase 1/2
- Study of AROSOD-1 in Adult Participants With Amyotrophic Lateral Sclerosis (ALS)WithdrawnNCT05949294Phase 1
- Study of ARO-RAGE in Healthy SubjectsCompletedNCT05533294Phase 1